HTG Molecular Diagnostics (HTGM) Tops Q2 EPS by 11c

HTG Molecular Diagnostics (NASDAQ: HTGM) reported Q2 EPS of ($0.54), $0.11 better than the analyst estimate of ($0.65). Revenue for the quarter came in at $1.49 million versus the consensus estimate of $2.35 million.

For earnings history and earnings-related data on HTG Molecular Diagnostics (HTGM) click here.

You May Also Be Interested In

• Tesla touts acceleration of new models, but Q1 results fall short of estimates
• Visa (V) Tops Q2 EPS by 7c, offers guidance
• Retail Opportunity Investments (ROIC) Tops Q1 EPS by 2c, reaffirms guidance